1. Medtech Insight
  2. >>Policy & Regulation

CMS Current Quality-Pay Programs Unlikely To Reward Device Innovations

Under 2015 legislation, CMS is intensely focused on tying payments to quality of care for patients seeing specialists such as gastroenterologists and cardiologists. But because the primary focus of alternative payment plans is on short-term patient outcomes, things like device durability or other long-term impacts from innovation won't easily be rewarded, a Medicare agency official told device-makers May 5.

It's going to be challenging for CMS to measure the quality that innovative devices provide as the Medicare agency moves to adapt physician-focused alternative payment models required by the 2015 Medicare Access and CHIP Reduction Act (MACRA), a CMS official told device-makers May 5.

"We want to be able to incentivize and provide rewards for people involved in true improvement activities … but there are a lot of things called 'improvement activities,' which really aren't," Kate Goodrich, CMS Director of the Center for Clinical Studies and Quality, told

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

More from Medtech Insight

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.